Tumor agnostic in Oncology

Molecular landscape of NTRK fusions in tumor agnostic

How to test for NTRK fusions?

ESMO proposal: NTRK testing1

It is important to ensure that the diagnostic test covers NTRK 1, 2, 3 fusion genes and is validated with appropriate reference standards.

[Figure adapted from Marchio C. et al , 2019.]

High-quality molecular testing is needed to uncover NTRK fusion+ cancer2,3,4

Marchio, et al. Ann Oncol 2019


1. Marchio C. et al. Ann Oncol 2019;30:1417–1427.

2. Vaishnavi A, Le AT, Doebele RC. Cancer Discov 2015;5:25–34.

3. Murphy DA, et al. Appl Immunohisochem Mol Morphol 2017;25:513–523.

4. Rogers TM, et al. Sci Rep 2017;7:1–8.

Welcome to Medically

The Roche Science Hub

This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.

Not a healthcare professional? Browse:

This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.